We have witnessed immense progress for lung cancer, such as screening, minimally invasive techniques for diagnosis and most important personalised customised treatment, in particular, the advances in new targeted therapies and new immunotherapies. These new treatments are reflected in the improved survival rates for patients. Next Generation Sequencing and Precision Oncology tools have been at the centre of this progress due to significant decoding of disease at the molecular genomic level.
Genetic Molecular Biomarker testing for somatic, disease-associated variants/mutations is recommended before starting therapy in eligible patients because targeted therapy has been shown to decrease tumour burden, decrease symptoms, and dramatically improve the quality of life for patients with specific somatic genomic alterations. Molecular testing is used to test for oncogenic genomic driver events for which targeted therapies are available.
